logo
logo
  • Home
  • About us
  • Story
  • Team
  • Our Approach
  • Careers
  • News
  • Contact
  • Investor Relations
  • PL
  • EN
      • Home
      • News

      News

      • Captor Therapeutics senior management to hold investor and partnering meetings around J.P. Morgan 41st Annual Healthcare Conference
        19.12.2022
        Captor Therapeutics senior management to hold investor and partnering meetings around J.P. Morgan 41st Annual Healthcare Conference
        more
      • Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
        24.11.2022
        Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
        more
      • Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases
        14.11.2022
        Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases
        more
      • Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
        20.09.2022
        Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
        more
      • Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
        05.09.2022
        Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
        more
      • Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
        10.08.2022
        Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
        more
      • Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
        21.07.2022
        Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
        more
      • Zaproszenie na Walne Zgromadzenie
        30.06.2022
        Zaproszenie na Walne Zgromadzenie
        more
      • Captor Therapeutics Q1 2022 report:  company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position
        31.05.2022
        Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position
        more
      • Captor Therapeutics to host R&D Day on May 18, 2022
        05.05.2022
        Captor Therapeutics to host R&D Day on May 18, 2022
        more
      • 1
      • 2
      • 3

      © 2018 Captor Therapeutics All rights reserved

      Design and implementation: Artneo.pl